Novel Molecular Therapeutics in Parkinson's Disease

Molecular and Cellular Therapeutics

Volumn , Issue , 2012, Pages 245-265

  Gonçalves, Susana ^a   Miranda, Hugo Vicente ^a   Outeiro, Tiago F ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Adeno associated viral vectors (AAVs); Glial cell linederived neurotrophic factor (GDNF); Lactoferrin (Lf); Novel molecular therapeutics; Parkinson's disease; Protein degradation systems; Protein folding systems

Indexed keywords

EID: 84886037660     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119967309.ch11     Document Type: Chapter

References (77)

1. Anderson, J. P.,Walker, D. E., Goldstein, J. M., et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem., 281, 29739-29752.
2. Auluck, P. K., Caraveo, G. and Lindquist, S. 2010. alpha-Synuclein: Membrane Interactions and Toxicity in Parkinson's Disease. Annu. Rev. Cell. Dev. Biol., 26, 211-233.
3. Beissinger, M. and Buchner, J. (1998) How chaperones fold proteins. Biol. Chem., 379, 245-259.
4. Beyer, K. (2006) Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol., 112, 237-251.
5. Bohren, K. M., Nadkarni, V., Song, J. H., et al. (2004) A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem., 279, 27233-27238.
6. Bonini, N. M. and Giasson, B. I. (2005) Snaring the function of alpha-synuclein. Cell, 123, 359-361.
7. Chandarlapaty, S., Sawai, A., Ye, Q., et al., (2008) SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res., 14, 240-248.
8. Chaturvedi, R. K. and Beal, M. F. (2008) PPAR: a therapeutic target in Parkinson's disease. J. Neurochem., 106, 506-518.
9. Chen, L., Periquet, M., Wang, X., et al. (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Invest, 119, 3257-3265.
10. Chung, C. Y., Koprich, J. B., Hallett, P. J. and Isacson, O. (2009) Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proc. Natl Acad. Sci. USA, 106, 22474-22479.
11. Cuervo, A. M., Stefanis, L., Fredenburg, R., et al. (2004) Impaired degradation of mutant alphasynuclein by chaperone-mediated autophagy. Science, 305, 1292-1295.
12. Cuervo, A. M., Wong, E. S. and Martinez-Vicente, M. (2010) Protein degradation, aggregation, and misfolding. Mov. Disord., 25 Suppl. 1, S49-54.
13. Dalfo, E., Gomez-Isla, T., Rosa, J. L., et al. (2004) Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice. J. Neuropathol. Exp. Neurol., 63, 302-313.
14. Dalfo, E., Portero-Otin, M., Ayala, V., et al. (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuropathol.Exp. Neurol., 64, 816-830.
15. De Oliveira, R. M., Pais, T. F. and Outeiro, T. F. (2010) Sirtuins: common targets in aging and in neurodegeneration. Curr. Drug Targets, 11, 1270-1280.
16. Dickey, C. A., Eriksen, J., Kamal, A., et al. (2005) Development of a high throughput drug screening assay for the detection of changes in tau levels-proof of concept with HSP90 inhibitors. Curr. Alzheimer Res., 2, 231-238.
17. Farrer, M. J. (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet., 7, 306-318.
18. Foust, K. D., Nurre, E., Montgomery, C. L., et al. (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol., 27, 59-65.
19. Fujikake, N., Nagai, Y., Popiel, H. A., et al. (2008) Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J. Biol. Chem., 283, 26188-26197.
20. Fujiwara, H., Hasegawa, M., Dohmae, N., et al. (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell. Biol., 4, 160-164.
21. Giasson, B. I., Duda, J. E., Murray, I. V., et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science, 290, 985-989.
22. Goetz, C. G., Poewe, W., Rascol, O. and Sampaio, C. (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov. Disord., 20, 523-539.
23. Haigis, M. C. and Sinclair, D. A. (2010) Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol., 5, 253-295.
24. Hartl, F. U. and Hayer-Hartl, M. (2002) Molecular chaperones in the cytosol: from nascent chain to folded protein. Science, 295, 1852-1858.
25. Hodara, R., Norris, E. H., Giasson, B. I., et al. (2004) Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem., 279, 47746-47753.
26. Horstink, M., Tolosa, E., Bonuccelli, U., et al. (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur. J. Neurol., 13, 1186-1202.
27. Huang, R., Ke, W., Liu, Y., et al. (2010) Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J. Neurol. Sc.i, 290, 123-130.
28. Imai, Y., Soda, M., Murakami, T., et al. (2003) A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death. J. Biol. Chem., 278, 51901-51910.
29. Inglis, K. J., Chereau, D., Brigham, E. F., et al. (2009) Polo-like kinase 2 (PLK2) phosphorylates alphasynuclein at serine 129 in central nervous system. J. Biol. Chem., 284, 2598-2602.
30. Kalmar, B. and Greensmith, L. (2009) Activation of the heat shock response in a primary cellular model of motoneuron neurodegeneration-evidence for neuroprotective and neurotoxic effects. Cell. Mol. Biol. Lett., 14, 319-335.
31. Kim, J., Yoon, Y. S., Lee, H. and Chang, J. W. (2008) AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease. Acta Neurochir. Suppl., 101, 99-105.
32. Klein, C. and Lohmann-Hedrich, K. (2007) Impact of recent genetic findings in Parkinson's disease. Curr. Opin. Neurol., 20, 453-464.
33. Ko, H. S., Bailey, R., Smith, W. W., et al. (2009) CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc. Natl Acad. Sci. USA, 106, 2897-2902.
34. Krantz, D. E., Peter, D., Liu, Y. and Edwards, R. H. (1997) Phosphorylation of a vesicular monoamine transporter by casein kinase II. J. Biol. Chem., 272, 6752-6759.
35. Kuhla, B., Boeck, K., Luth, H. J., et al. (2006) Age-dependent changes of glyoxalase I expression in human brain. Neurobiol. Aging, 27, 815-822.
36. Kumar, P., Wu, H., Mcbride, J. L., et al. (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature, 448, 39-43.
37. Kuwahara, T., Koyama, A., Koyama, S., et al. (2008) A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. Hum. Mol. Genet., 17, 2997-3009.
38. Lanka, V., Wieland, S., Barber, J. and Cudkowicz, M. (2009) Arimoclomol: a potential therapy under development for ALS. Expert Opin. Investig. Drugs, 18, 1907-1918.
39. Lim, K. L., Chew, K. C., Tan, J. M., et al. (2005) Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci., 25, 2002-2009.
40. Lindvall, O. andWahlberg, L. U. (2008) Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp. Neurol., 209, 82-88.
41. Liu,W., Vives-Bauza, C., Acin-Perez, R., et al. (2009) PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One, 4, e4597.
42. Liu, Y., Fallon, L., Lashuel, H. A., et al. (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell, 111, 209-218.
43. Lozano, A. M., Snyder, B. J., Hamani, C., et al. (2010) Basal ganglia physiology and deep brain stimulation. Mov. Disord., 25 Suppl. 1, S71-75.
44. Maeta, K., Mori, K., Takatsume, Y., et al. (2005) Diagnosis of cell death induced by methylglyoxal, a metabolite derived from glycolysis, in Saccharomyces cerevisiae. FEMS Microbiol. Lett., 243, 87-92.
45. Mandemakers, W., Morais, V. A. and De Strooper, B. (2007) A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J. Cell. Sci., 120, 1707-1716.
46. Neuwelt, E., Abbott, N. J., Abrey, L., et al. (2008) Strategies to advance translational research into brain barriers. Lancet Neurol., 7, 84-96.
47. Nichols, W. C., Elsaesser, V. E., Pankratz, N., et al. (2007) LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology, 69, 1737-1744.
48. Nuytemans, K., Theuns, J., Cruts, M. and Van Broeckhoven, C. (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. Mutat., 31, 763-780.
49. Okawa, Y., Hideshima, T., Steed, P., et al. (2009) SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumour cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumours by abrogating signaling via Akt and ERK. Blood, 113, 846-855.
50. Olanow, C. W., Agid, Y., Mizuno, Y., et al. (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Disord., 19, 997-1005.
51. Pan, X., Gong, N., Zhao, J., et al. (2010) Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain, 133, 1342-1351.
52. Pronin, A. N., Morris, A. J., Surguchov, A. and Benovic, J. L. (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem., 275, 26515-26522.
53. Putcha, P., Danzer, K. M., Kranich, L. R., et al. (2010) Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J. Pharmacol. Exp. Ther., 332, 849-857.
54. Ramsey, C. P. and Giasson, B. I. (2008) The E163K DJ-1 mutant shows specific antioxidant deficiency. Brain Res., 1239, 1-11.
55. Rodriguez, M. S., Dargemont, C. and Hay, R. T. (2001) SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem., 276, 12654- 12659.
56. Rott, R., Szargel, R., Haskin, J., et al. (2008) Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J. Biol. Chem., 283, 3316- 3328.
57. Sampathu, D. M., Giasson, B. I., Pawlyk, A. C., et al. (2003) Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am. J. Pathol., 163, 91-100.
58. Schneider, B., Zufferey, R. and Aebischer, P. (2008) Viral vectors, animal models and new therapies for Parkinson's disease. Parkinsonism Relat. Disord., 14 Suppl. 2, S169-171.
59. Shimura, H., Hattori, N., Kubo, S., et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet., 25, 302-305.
60. Singer, M. A. and Lindquist, S. (1998) Multiple effects of trehalose on protein folding in vitro and in vivo. Mol. Cell, 1, 639-648.
61. Souza, J. M., Giasson, B. I., Chen, Q., et al. (2000) Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem., 275, 18344-18349.
62. Spencer, B. J. and Verma, I. M. (2007) Targeted delivery of proteins across the blood-brain barrier. Proc. Natl Acad. Sci. USA, 104, 7594-7599.
63. Spillantini, M. G., Schmidt, M. L., Lee, V. M., et al. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
64. Storch, A., Jost,W. H., Vieregge, P., et al. (2007) Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch. Neurol., 64, 938-944.
65. Su, H. L. and Li, S. S. (2002) Molecular features of human ubiquitin-like SUMOgenes and their encoded proteins. Gene, 296, 65-73.
66. Tatham, M. H., Jaffray, E., Vaughan, O. A., et al. (2001) Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem., 276, 35368-35374.
67. Thornalley, P. J. (1998) Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem. Biol. Interact., 111-112, 137-151.
68. Tofaris, G. K., Layfield, R. and Spillantini, M. G. (2001) alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett., 509, 22-6.
69. Valente, E. M., ABOUSleiman, P. M., Caputo, V., et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304, 1158-1160.
70. Vicente Miranda, H. and Outeiro, T. F. (2010) The sour side of neurodegenerative disorders: the effects of protein glycation. J. Pathol., 221, 13-25.
71. Webb, J. L., Ravikumar, B., Atkins, J., et al. (2003) Alpha-Synuclein is degraded by both autophagy and the proteasome. J.Biol. Chem., 278, 25009-25013.
72. Weihofen, A., Thomas, K. J., Ostaszewski, B. L., et al. (2009) Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry, 48, 2045-2052.
73. Williams, A., Gill, S., Varma, T., et al. (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, openlabel trial. Lancet Neurol., 9, 581-591.
74. Xilouri, M., Vogiatzi, T., Vekrellis, K., et al. (2009) Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One, 4, e5515.
75. Zerial, M. and Mcbride, H. (2001) Rab proteins as membrane organizers. Nat. Rev. Mol. Cell. Biol., 2, 107-117.
76. Zhang, Y., Schlachetzki, F. and Pardridge, W. M. (2003) Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther., 7, 11-18.
77. Zhu, M. and Fink, A. L. (2003) Lipid binding inhibits alpha-synuclein fibril formation. J. Biol. Chem., 278, 16873-16877.